Disease-adapted relapse therapy for ovarian cancer: results of a prospective study
Standard
Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. / Kuhn, W; Schmalfeldt, B; Pache, L; Späthe, K; Ulm, K; Renziehausen, K; Nöschel, H; Canzler, E; Richter, B; Kroner, M; Tilch, G; Janicke, F; Graeff, H.
In: INT J ONCOL, Vol. 13, No. 1, 07.1998, p. 57-63.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Disease-adapted relapse therapy for ovarian cancer: results of a prospective study
AU - Kuhn, W
AU - Schmalfeldt, B
AU - Pache, L
AU - Späthe, K
AU - Ulm, K
AU - Renziehausen, K
AU - Nöschel, H
AU - Canzler, E
AU - Richter, B
AU - Kroner, M
AU - Tilch, G
AU - Janicke, F
AU - Graeff, H
PY - 1998/7
Y1 - 1998/7
N2 - Primary therapy of advanced ovarian cancer is standardized, the therapy in relapsed ovarian cancer however is still controversial. In a prospective study the benefit of secondary surgery and/or second-line chemotherapy were evaluated. 139 patients with relapsed ovarian cancer were stratified according to a treatment plan: patients with early relapse (recurrence-free interval 12 months) or primary progression during chemotherapy (n=43) were treated chemotherapeutically with etoposide (p.o. vs. i.v.). Patients with late relapse (recurrence-free interval >12 months, n=96) were referred, if possible, to a secondary debulking operation, followed by a platinum-based chemotherapy. Remission-rate, toxicity and survival time were analyzed. Median survival time in the group was 15 months compared to 30 months in patients with late relapse (p=0.0004). Within the group patients with secondary debulking and chemotherapy (n=59) had a statistically significant survival advantage compared to patients who had only chemotherapy (n=37) (38 vs. 12 months, p<0.0001). The unfavorable group of patients with early relapse should be treated chemotherapeutically, whereas in patients with late relapse a secondary debulking seems to improve prognosis.
AB - Primary therapy of advanced ovarian cancer is standardized, the therapy in relapsed ovarian cancer however is still controversial. In a prospective study the benefit of secondary surgery and/or second-line chemotherapy were evaluated. 139 patients with relapsed ovarian cancer were stratified according to a treatment plan: patients with early relapse (recurrence-free interval 12 months) or primary progression during chemotherapy (n=43) were treated chemotherapeutically with etoposide (p.o. vs. i.v.). Patients with late relapse (recurrence-free interval >12 months, n=96) were referred, if possible, to a secondary debulking operation, followed by a platinum-based chemotherapy. Remission-rate, toxicity and survival time were analyzed. Median survival time in the group was 15 months compared to 30 months in patients with late relapse (p=0.0004). Within the group patients with secondary debulking and chemotherapy (n=59) had a statistically significant survival advantage compared to patients who had only chemotherapy (n=37) (38 vs. 12 months, p<0.0001). The unfavorable group of patients with early relapse should be treated chemotherapeutically, whereas in patients with late relapse a secondary debulking seems to improve prognosis.
KW - Adult
KW - Aged
KW - Antineoplastic Agents, Phytogenic
KW - Combined Modality Therapy
KW - Disease-Free Survival
KW - Etoposide
KW - Female
KW - Humans
KW - Middle Aged
KW - Ovarian Neoplasms
KW - Prognosis
KW - Prospective Studies
KW - Recurrence
KW - Time Factors
M3 - SCORING: Journal article
C2 - 9625803
VL - 13
SP - 57
EP - 63
JO - INT J ONCOL
JF - INT J ONCOL
SN - 1019-6439
IS - 1
ER -
